Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Herr

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer CenterH S Puc, R Heelan, M Mazumdar, et al.
The Journal of Urology|March 1, 1992
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary GroupT A Splinter, H I Scher, L Denis, et al.
Cancer|March 1, 1991
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)R J Motzer, N L Geller, C C Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1986
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumorsG J Bosl, R Gluckman, N L Geller, et al.
Oncology (Williston Park, N.Y.)|August 12, 1998
NCCN urothelial cancer practice guidelines. National Comprehensive Cancer NetworkH Scher, R Bahnson, S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1987
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumorsG J Bosl, N L Geller, N J Vogelzang, et al.
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Annals of Internal Medicine|April 1, 1988
Advanced seminoma: the role of chemotherapy and adjunctive surgeryR J Motzer, G J Bosl, N L Geller, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer CenterH S Puc, R Heelan, M Mazumdar, et al.
The Journal of Urology|March 1, 1992
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary GroupT A Splinter, H I Scher, L Denis, et al.
Cancer|March 1, 1991
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)R J Motzer, N L Geller, C C Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1986
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumorsG J Bosl, R Gluckman, N L Geller, et al.
Oncology (Williston Park, N.Y.)|August 12, 1998
NCCN urothelial cancer practice guidelines. National Comprehensive Cancer NetworkH Scher, R Bahnson, S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1987
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumorsG J Bosl, N L Geller, N J Vogelzang, et al.
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Annals of Internal Medicine|April 1, 1988
Advanced seminoma: the role of chemotherapy and adjunctive surgeryR J Motzer, G J Bosl, N L Geller, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 15